We found that genetic variants in the HMGCR region, serving as proxies for targets of statin therapy, were associated with a 26% decrease in risk of overall cancer per standard deviation (around 39 mg/dL or 1.0 mmol/L) reduction in genetically-predicted LDL-cholesterol. Here, HMGCR is linked to cancer.